Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, tolerability, and immunogenicity of V114 in healthy Japanese infants has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• V114 (15-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2022-11-15